Amryt Pharma advancing on multiple fronts

0
16
  • Amryt Pharma third-quarter revenue up over 14% on soaring metreleptin sales
  • Amryt Pharma impresses broker at Capital Markets Day
  • Amryt Pharma hail rocketing revenue growth ‘we’re a biotech that makes money’
Amryt Pharma PLC -

Quick facts: Amryt Pharma PLC

Follow

View company profile

Amryt is a global commercial-stage biopharmaceutical company focused on acquiring, developing and commercializing innovative treatments to help improve the lives of patients with rare and orphan diseases.

The company has a strong and growing portfolio of commercial and development assets.

03 Nov 2021

Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT) announced revenue growth of 14.6% for the third quarter after sales of its lipodystrophy treatment metreleptin soared 21.5%.

Revenue rose to US$56.5mln in the three months to end-September from US$49.3mln in the same period last year.

Metreleptin revenues rocketed by 21.5% to US$36.3mln in the third quarter. Excluding Latin America, where ordering has been sporadic, sales of the drug were 51.6% higher.

The biopharma company, which specialises in rare diseases, reaffirmed its full-year revenue guidance of UD$220mln-US$225mln, representing year-on-year growth of 20%-23%.

Read more

22 Oct 2021

(, ) announced its support for Global Epidermolysis Bullosa (EB) Awareness Week, which is taking place October 25 – 31, 2021.

Joe Wiley, Amryt’s chief executive, said: “Epidermolysis Bullosa is a very distressing condition which severely impacts the lives of those living with EB and also has a profound impact on parents, families and all those involved in their care.

Read more

19 Oct 2021

Amryt has extended the patents on its lead development candidate, Oleogel-S10 and its recently acquired commercial product, Mycapssa.

For Oleogel-S10, a treatment for skin condition EB, the US patent office has issued a new formulation patent to Amryt, which will be listable in the Approved Drug Products or “Orange Book”. This patent will expire in January 2039.

Read more

14 Sep 2021

Amryt Pharma has had its price target of US$40 and ‘buy’ rating reiterated by Canaccord after the company hosted a virtual capital markets day.

Opinion leaders spoke on the near-term growth opportunities with Filsuvez in epidermolysis bullosa (EB) and Mycapssa in acromegaly, said the broker, which has underlined its optimistic view.

The broker continues to expect US approval of Filsuvez in EB on its November 30 PDUFA date, which should serve as a significant catalyst for the share price.

Read more

03 Nov 2021

Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT)‘s Joe Wiley talks to Proactive London’s Katie Pilbeam after reporting revenue growth of 14.6% for the third quarter after sales of its lipodystrophy treatment metreleptin soared 21.5%.

Revenue rose to US$56.5mln in the three months to end-September from US$49.3mln in the same period last year.

Much of this performance is down to Metreleptin where revenues rocketed by 21.5% to US$36.3mln in the third quarter. Excluding Latin America, where ordering has been sporadic, sales of the drug were 51.6% higher.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Amryt Pharma hail rocketing revenue growth ‘we’re a biotech that makes money’

Amryt Pharma PLC (AIM:AMYT, NASDAQ:AMYT)’s Joe Wiley talks to Proactive London’s Katie Pilbeam after reporting revenue growth of 14.6% for the third quarter after sales of its lipodystrophy treatment metreleptin soared 21.5%.

Revenue rose to US$56.5mln in the three months to end-September…

2 hours, 29 minutes ago

3 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here